11 results on '"Leinonen J"'
Search Results
2. Detection of prostatic cells in peripheral blood: correlation with serum concentrations of prostate-specific antigen
- Author
-
Jaakkola, S, primary, Vornanen, T, primary, Leinonen, J, primary, Rannikko, S, primary, and Stenman, U H, primary
- Published
- 1995
- Full Text
- View/download PDF
3. Time-resolved immunofluorometric assay of trypsin-2 complexed with alpha 1-antitrypsin in serum
- Author
-
Hedström, J, primary, Leinonen, J, primary, Sainio, V, primary, and Stenman, U H, primary
- Published
- 1994
- Full Text
- View/download PDF
4. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin
- Author
-
Leinonen, J, primary, Lövgren, T, primary, Vornanen, T, primary, and Stenman, U H, primary
- Published
- 1993
- Full Text
- View/download PDF
5. Immunopeptidometric assay for enzymatically active prostate-specific antigen.
- Author
-
Wu P, Zhu L, Stenman UH, and Leinonen J
- Subjects
- Female, Fluoroimmunoassay, Glutathione Transferase genetics, Humans, Isoenzymes blood, Male, Peptide Library, Peptides blood, Prostate-Specific Antigen genetics, Protein Precursors blood, Recombinant Fusion Proteins, Prostate-Specific Antigen blood, Prostate-Specific Antigen metabolism
- Abstract
Background: Determinations of certain forms of prostate-specific antigen (PSA) have been shown to increase the specificity for prostate cancer (PCa). One such variant, proteolytically active PSA, is a potentially useful tumor marker, but it is not specifically recognized by antibodies. Using phage display libraries, we previously identified a "family" of peptides that bind specifically to active PSA. We used these to develop an immunopeptidometric assay (IPMA) that specifically detects this form of PSA., Methods: Microtitration plates coated with a PSA antibody were used to capture PSA, and a PSA-binding glutathione S-transferase (GST) fusion peptide was used as a tracer. Bound tracer was detected with an antibody to GST labeled with a europium chelate. PSA isoenzymes with high and low enzymatic activity were used to study binding specificity., Results: The IPMA detected enzymatically active PSA but not internally cleaved PSA and pro-PSA, which are enzymatically inactive. The assay detected 1-10% of free PSA in serum from PCa patients., Conclusions: Peptides identified by phage display can be used to develop assays with unique specificities for enzymatically active PSA. IPMA represents a new assay principle with wide potential utility.
- Published
- 2004
- Full Text
- View/download PDF
6. Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1-antichymotrypsin complex together with free or total PSA.
- Author
-
Zhu L, Leinonen J, Zhang WM, Finne P, and Stenman UH
- Subjects
- Aged, Animals, Antibodies, Monoclonal isolation & purification, False Positive Reactions, Female, Fluoroimmunoassay, Humans, Male, Mice, Mice, Inbred BALB C, Middle Aged, Prostatic Hyperplasia diagnosis, Prostatic Neoplasms diagnosis, Protein Binding, ROC Curve, Reproducibility of Results, Sensitivity and Specificity, Prostate-Specific Antigen blood, alpha 1-Antichymotrypsin blood
- Abstract
Background: A major portion of prostate-specific antigen exists in circulation as a complex with alpha(1)-antichymotrypsin (PSA-ACT), whereas a minor part is free (fPSA). The proportion of PSA-ACT is increased in prostate cancer (PCa), but immunologic determination of PSA-ACT is hampered by a background produced by nonspecific adsorption of ACT to the solid phase. To reduce the nonspecific interference, we produced an antibody specific for complexed ACT and developed immunofluorometric assays (IFMAs) for simultaneous measurement of fPSA + PSA-ACT (fPSA/PSA-ACT) and PSA-ACT + total PSA (tPSA, PSA-ACT/tPSA)., Methods: Monoclonal antibodies (MAbs) were produced by immunization with PSA-ACT. The dual-label time-resolved IFMAs for fPSA/PSA-ACT and PSA-ACT/tPSA used a capture MAb to tPSA, an Eu(3+)-labeled MAb to fPSA or complexed ACT, and an Sm(3+)-labeled MAb to complexed ACT or to tPSA as tracer antibodies. The clinical utility was evaluated using serum samples from individuals with or without PCa with PSA concentrations of 2.0-20.0 micro g/L., Results: One MAb (1D10) showed low cross-reactivity with free ACT and cathepsin G-ACT. A sandwich assay for PSA-ACT with 1D10 as tracer had a detection limit of 0.05 micro g/L, and with this assay, PSA-ACT was undetectable in female sera. The detection limit for fPSA was 0.004 micro g/L. Determinations of the ratio of fPSA to PSA-ACT and the proportions of fPSA/tPSA and PSA-ACT/tPSA provided the same clinical specificity for PCa and provided significantly better clinical specificity than did tPSA., Conclusions: Background problems observed in earlier PSA-ACT assays are eliminated by the use of a MAb specific for complexed ACT as a tracer. The same clinical validity can be obtained by determination of fPSA or PSA-ACT together or in combination with tPSA.
- Published
- 2003
- Full Text
- View/download PDF
7. Epitope mapping of antibodies against prostate-specific antigen with use of peptide libraries.
- Author
-
Leinonen J, Wu P, and Stenman UH
- Subjects
- Amino Acid Sequence, Epitope Mapping, Models, Molecular, Molecular Sequence Data, Peptide Library, Antibodies, Monoclonal chemistry, Prostate-Specific Antigen immunology
- Abstract
Background: Prostate-specific antigen (PSA) is the most important marker for prostate cancer, but PSA concentrations determined by various assays can differ significantly because of differences in specificity of the antibodies used. To identify epitopes recognized by various monoclonal antibodies (MAbs) to PSA, we have isolated peptides that react with the paratopes of these., Methods: Six anti-PSA MAbs representing three major epitope groups were screened with five cyclic phage display peptide libraries. After selection, the peptide sequences were determined by sequencing of the relevant part of viral DNA. Binding of the phage peptides to the MAbs was monitored by immunoassay., Results: For each MAb, several paratope-binding peptides with distinct sequence motifs were identified, but only approximately 10% showed similarity with the PSA sequence. Some of these correctly predicted the location of the epitopes. By sequential panning of the library with two closely related MAbs, we identified peptides reacting equally with both MAbs. When analyzed against a large panel of PSA MAbs, the peptides generally showed restricted specificity toward the MAb used for selection, but some peptides bound to several related MAbs., Conclusions: Most of the cyclic peptides selected with PSA MAbs are specific for the MAb used for selection and do not resemble any sequence on the antigen. Peptides reactive with two MAbs recognizing the same epitope can be obtained by sequential panning. This method can be used to predict the location of some epitopes, but additional methods are needed to confirm the result.
- Published
- 2002
8. Time-resolved immunofluorometric assay of trypsin-1 complexed with alpha(1)-antitrypsin in serum: increased immunoreactivity in patients with biliary tract cancer.
- Author
-
Hedström J, Haglund C, Kemppainen E, Leinimaa M, Leinonen J, and Stenman UH
- Subjects
- Biliary Tract Diseases blood, Biomarkers, Tumor blood, CA-19-9 Antigen blood, Fluoroimmunoassay methods, Humans, Isoenzymes blood, Pancreatic Neoplasms blood, Reproducibility of Results, Sensitivity and Specificity, Trypsinogen blood, Biliary Tract Neoplasms blood, Trypsin blood, alpha 1-Antitrypsin metabolism
- Abstract
Background: Increased serum concentrations of trypsin immunoreactivity occur in patients with biliary tract cancer. To characterize this trypsin, we developed a sensitive time-resolved immunofluorometric assay for trypsin-1 complexed with alpha(1)-antitrypsin (AAT) and studied the concentrations of this complex in sera from healthy individuals (n = 130) and patients with benign biliary disease (n = 32), biliary tract cancer (n = 17), pancreatic cancer (n = 27), and hepatocellular cancer (n = 12)., Methods: We used a trypsin-1-specific monoclonal antibody on the solid phase and a europium-labeled polyclonal antibody to AAT as tracer. The detection limit was 0.42 microgram/L. The validity of the trypsin-1-AAT test for detection of biliary tract cancer was compared with trypsin-2-AAT and CA19-9., Results: Increased concentrations of trypsin-1-AAT (>33 microgram/L) were found in 76% of patients with biliary tract cancer, and the concentrations were significantly higher than in those with benign biliary disease (P <0. 0001). The median concentration of trypsin-1-AAT in serum from patients with biliary tract cancer was 3.7-fold higher than in healthy controls, 2.6-fold higher than in patients with benign biliary tract disease, 1.7-fold higher than in patients with pancreatic cancer, and 2.0-fold higher than in patients with hepatocellular cancer., Conclusions: Of the markers studied, trypsin-1-AAT had the largest area (0.83) under the receiver operating curve in differentiating biliary tract cancer from benign biliary tract disease. Our results suggest that trypsin-1-AAT is a new potential marker for biliary tract cancer.
- Published
- 1999
9. Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum.
- Author
-
Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, and Stenman UH
- Subjects
- Electrophoresis, Polyacrylamide Gel, Fluoroimmunoassay, Humans, Immunoblotting, Male, Prostate-Specific Antigen metabolism, Prostatic Hyperplasia blood, Prostatic Neoplasms blood, Protein Binding, alpha 1-Antichymotrypsin blood, alpha 1-Antichymotrypsin metabolism, alpha 1-Antitrypsin metabolism, Prostate-Specific Antigen blood, alpha 1-Antitrypsin analysis
- Abstract
Background: Prostate-specific antigen (PSA) occurs in serum both free and in complex with protease inhibitors. The complex with alpha1-antichymotrypsin (ACT) is the major form in serum, and the proportion of PSA-ACT is higher in prostate cancer (PCa) than in benign prostatic hyperplasia (BPH). PSA also forms a complex with alpha1-protease inhibitor (API) in vitro, and the PSA-ACT complex has been detected in serum from patients with prostate cancer. The aim of the present study was to develop a quantitative method for the determination of PSA-API and to determine the serum concentrations in patients with PCa and BPH., Methods: The assay for PSA-API utilizes a monoclonal antibody to PSA as capture and a polyclonal antibody to API labeled with a Eu-chelate as a tracer. For calibrators, PSA-API formed in vitro was used. Serum samples were obtained before treatment from 82 patients with PCa, from 66 patients with BPH, and from 22 healthy females., Results: The concentrations of PSA-API are proportional to the concentrations of total PSA. PSA-API comprises 1.0-7.9% (median, 2.4%) of total immunoreactive PSA in PCa and 1.3-12.2% (median, 3.6%) in BPH patients with serum PSA concentrations >4 microgram/L. In patients with 4-20 microgram/L total PSA, the proportion of PSA-API serum is significantly higher in BPH (median, 4.1%) than in PCa (median, 3. 2%; P = 0.02)., Conclusions: The proportion of PSA-API in serum is lower in patients with PCa than in those with BPH. These results suggest that PSA-API is a potential adjunct to total and free PSA in the diagnosis of prostate cancer.
- Published
- 1999
10. Characterization of monoclonal antibodies for prostate-specific antigen and development of highly sensitive free prostate-specific antigen assays.
- Author
-
Black MH, Grass CL, Leinonen J, Stenman UH, and Diamandis EP
- Subjects
- Animals, Cross Reactions, Epitopes, Fluoroimmunoassay methods, Humans, Kallikreins analysis, Kallikreins immunology, Male, Mice, Mice, Inbred BALB C, Prostate-Specific Antigen immunology, Reagent Kits, Diagnostic, Tissue Kallikreins, Antibodies, Monoclonal, Prostate-Specific Antigen blood
- Abstract
Background: The recent elucidation of the importance of serological free prostate-specific antigen (PSA) in the diagnosis of prostate cancer has created a demand for immunoassays specific for free PSA., Methods: We developed and characterized 11 monoclonal antibodies with high affinities for PSA (Ka values from 1.1 x 10(8) to 1.8 x 10(10)L/mol), only 3 of which cross-react with human glandular kallikrein (hK2). Using these antibodies and PSA antibodies developed by others, in conjunction with time-resolved fluorometry, we developed ultrasensitive sandwich immunoassays specific for the free form of PSA., Results: The analytical detection limit of these immunoassays is 0.001 microg/L. To our knowledge, this is the most sensitive free PSA assay reported to date. The free PSA immunoassays exhibit <1% cross-reactivity with PSA-alpha1-antichymotrypsin, show no cross-reactivity with hK2, and correlate well with established free PSA kits. The 11 antibodies developed by our group, in conjunction with 4 commercially available antibodies, were used to generate a putative epitope map of the PSA molecule., Conclusion: The highly sensitive free PSA immunoassays may be used for measuring PSA subfractions in female serum, an application currently impossible with other reported free PSA immunoassays.
- Published
- 1999
11. Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin.
- Author
-
Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Rannikko S, and Stenman UH
- Subjects
- Aged, Aged, 80 and over, Female, Fluoroimmunoassay, Humans, Immunoblotting, Immunosorbent Techniques, Male, Middle Aged, Prostate-Specific Antigen chemistry, Prostatic Hyperplasia blood, Prostatic Neoplasms blood, Protein Denaturation, ROC Curve, Reproducibility of Results, Sensitivity and Specificity, Sodium Hydroxide, alpha-Macroglobulins chemistry, Prostate-Specific Antigen blood, alpha-Macroglobulins metabolism
- Abstract
Prostate-specific antigen (PSA) rapidly forms a complex with alpha2-macroglobulin (A2M) in vitro; however, PSA complexed with A2M (PSA-A2M) is not detected by conventional immunoassays for PSA because it is encapsulated by the A2M. In this study, we show that denaturation of PSA-A2M at high pH renders PSA immunoreactive. Part of the complexed PSA is released in free form and part remains bound to denatured A2M. These forms can be measured by a conventional immunoassay for PSA. This finding enabled us to design a dissociation assay for the detection of PSA-A2M, which was based on the removal of immunoreactive PSA in serum by immunoadsorption, denaturation of PSA-A2M at high pH, and measurement of the released PSA immunoreactivity by a conventional PSA immunoassay. This PSA-A2M assay was calibrated with PSA-A2M formed in vitro. The detection limit of the assay was 0.14 microg/L. Inter- and intraassay coefficients variation were 4-9% and 8-14%, respectively. When purified PSA was incubated with A2M, the loss of PSA immunoreactivity was highly correlated with the PSA-A2M formed, as measured by the dissociation assay for PSA-A2M (r = 0.99; P <0.0001). The concentration of PSA-A2M in serum correlated with that of total PSA both in prostate cancer (PCa) and benign prostatic hyperplasia (BPH); however, the ratio of PSA-A2M in relation to total PSA was significantly higher in BPH than in PCa (P <0.0003). ROC curve analysis suggested that measurement of the ratio of PSA-A2M to total PSA in serum improves the diagnostic accuracy for PCa compared with assays for total PSA only.
- Published
- 1998
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.